Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma with double‐hit MYC and BCL2 or BCL6 and triple hit

Key Points

• The aim is to analyze clinicopathological and transcriptomic profiles in patients with various diffuse large B-cell lymphoma subtypes.
• Characterized 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma.
• Separated patients into groups based on MYC, BCL2, and BCL6 expression.
• Conducted survival analysis for each lymphoma subtype.
• Identified distinct survival outcomes between DLBCL/HGBCL-DH-BCL6 and DLBCL/HGBCL-DH-BCL2.
• Noted that DLBCL/HGBCL-TH has the worst survival rates.
• Recommended testing for all three genes in the diagnosis of DLBCL/HGBCL.